Analytical Data
-
基因名
SGCG
- Application
-
别名
35 kDa dystrophin associated glycoprotein; 35 kDa dystrophin-associated glycoprotein; 35DAG; 35kD dystrophin associated glycoprotein; 35kDa dystrophin-associated glycoprotein; A4; DAGA4; DMDA; DMDA1; Gamma SG; Gamma-sarcoglycan; Gamma-SG; LGMD2C; MAM ; MGC130048; Sarcoglycan gamma; SCARMD2; SCG3; SGCG; SGCG_HUMAN; TYPE
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q13326
-
表达区间
1-291 aa
-
氨基酸序列
MVREQYTTATEGICIERPENQYVYKIGIYGWRKRCLYLFVLLLLIILVVNLALTIWILKVMWFSPAGMGHLCVTKDGLRLEGESEFLFPLYAKEIHSRVDSSLLLQSTQNVTVNARNSEGEVTGRLKVGPKMVEVQNQQFQINSNDGKPLFTVDEKEVVVGTDKLRVTGPEGALFEHSVETPLVRADPFQDLRLESPTRSLSMDAPRGVHIQAHAGKIEALSQMDILFHSSDGMLVLDAETVCLPKLVQGTWGPSGSSQSLYEICVCPDGKLYLSVAGVSTTCQEHSHICL
-
分子量
58.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCG, or sarcoglycan gamma, is a crucial component of the dystrophin-glycoprotein complex, which plays a vital role in maintaining the structural integrity of muscle cells. Mutations in the SGCG gene are associated with limb-girdle muscular dystrophy type 2C (LGMD2C), a genetic disorder that leads to progressive muscle weakness and degeneration. Research on SGCG recombinant proteins has emerged to better understand its function, the molecular mechanisms underlying its role in muscle integrity, and the pathophysiology of associated muscular dystrophies. The development of SGCG recombinant proteins facilitates the exploration of potential therapeutic approaches, including gene therapy and protein replacement strategies, aimed at restoring the function of defective proteins in patients. Moreover, these recombinant proteins serve as valuable tools for studying the interactions within the dystrophin-glycoprotein complex and evaluating the efficacy of novel treatments. As the knowledge surrounding SGCG continues to expand, it holds promise for advancing our understanding of muscular dystrophies and developing targeted interventions that could improve patient outcomes. This research is crucial not only for identifying potential biomarkers for LGMD2C but also for designing effective therapeutic strategies that could ameliorate the symptoms associated with the disease, ultimately enhancing the quality of life for affected individuals.
